News

The combination of nivolumab and ipilimumab with chemotherapy shows significant long-term survival benefits in metastatic NSCLC, irrespective of PD-L1 expression or histology, as per updated 5-year data.

The combination of the adenovirus CAN-2409 and valacyclovir with continued immune checkpoint inhibitor therapy demonstrated favorable tolerability and induced a positive immune response.

A daratumumab-VRd–based regimen boosted the rate of MRD-negativity in patients with newly diagnosed, transplant-eligible multiple myeloma.

Tarah Ballinger, MD, discusses findings from the phase 2 EAZ171 study of taxane-induced peripheral neuropathy in Black patients with breast cancer.

Treatment with ARV-766, an investigational proteolysis targeting chimera (PROTAC) androgen receptor degrader, led to a ≥50% PSA decline in 43% of patients with metastatic castration-resistant prostate cancer.

The IMROZ trial reveals significant improvements in PFS for patients with newly diagnosed, transplant-ineligible multiple myeloma.

A clinical complete response was observed in all 42 patients with locally advanced mismatch repair–deficient rectal cancer who completed treatment with the dostarlimab in a phase 2 study.

Perioperative nivolumab led to a significant improvement in event-free survival in the phase 3 CheckMate 77T trial in patients with stage III N2 and stage III non-N2 non–small cell lung cancer.

Datopotamab deruxtecan was efficacious among patients with non-small cell lung cancer and baseline brain metastases who harbor actionable genomic alterations, according to an exploratory analysis of the phase 2 TROPION-Lung05 trial.

Five-year follow-up from the IMpower010 trial shows atezolizumab improves overall survival vs BSC in resected stage IB-IIIA NSCLC.

A new radioligand therapy, JNJ-6420, shows promise in treating metastatic castration-resistant prostate cancer with deep and lasting responses after just 1-2 doses.

According to findings from the phase 3 ESOPEC trial, perioperative chemotherapy given with FLOT improved overall survival in resectable esophageal cancer.

Linvoseltamab may have similar — if not better — outcomes compared with teclistamab for patients with triple-class exposed relapsed or refractory multiple myeloma.

A retrospective analysis of the phase 3 IMmotion010 trial suggests that KIM-1 levels might hold promise as a biomarker in renal cell carcinoma.

Lenvatinib in combination with pembrolizumab yielded a greater clinical benefit rate compared with sunitinib in advanced clear cell renal cell carcinoma, regardless of patient biomarker subtype.

Envafolimab given subcutaneously with lenvatinib shows promise in patients with advanced endometrial cancer who were not microsatellite instability-high or mismatch repair deficient after prior lines of therapy.

Data from DREAMM-7 showed comparable patient-reported outcomes between belantamab/bortezomib/dexamethasone and daratumumab/bortezomib/dexamethasone in relapsed/refractory multiple myeloma.

A step-up dosing regimen of teclistamab with prophylactic tocilizumab for relapsed/refractory multiple myeloma showed promising responses in a small patient cohort.

A study found that enfortumab vedotin with pembrolizumab significantly improves survival and maintains quality-of-life compared with chemotherapy for locally advanced or metastatic urothelial cancer.

Treatment with talquetamab demonstrated promising safety and efficacy findings when used in relapsed/refractory multiple myeloma, including patients with comorbidities and poor functional status.

PolyPEPI1018 given in combination with atezolizumab showed tolerability and induced immune responses in patients with relapsed/refractory microsatellite-stable metastatic colorectal cancer.

Retreatment with daratumumab showed response rates similar to overall response rates from initial daratumumab-based regimens in a retrospective study.

Rebecca Shatsky, MD, discusses findings from the ISPY2.2 trial presented at the 2024 ASCO Annual Meeting.

In a phase 3 trial, BVd demonstrated a substantial improvement in progression-free survival compared with DVd for patients with relapsed/refractory multiple myeloma.

Based on a post-hoc analysis of the ARAMIS trial, darolutamide was associated with lower rates of PSA and radiological progression vs placebo as well as improving overall survival in patients with nonmetastatic castration-resistant prostate cancer.

With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative tumor infiltrating lymphocytes did not serve as a biomarker of improved clinical outcomes of nivolumab plus ipilimumab in metastatic ccRCC.

The addition of liver transplantation to chemotherapy led to improved overall survival at 5 years in patients with definitively unresectable colorectal cancer metastasis in the liver.

Trastuzumab deruxtecan therapy led to superior PFS vs chemotherapy in pretreated, HR-positive, HER2-low metastatic breast cancer as well as ‘ultralow’ disease with IHC 0 and membrane staining.

Patients with ROS1-positive non–small cell lung cancer responded to the next-generation inhibitor taletrectinib with acceptable toxicity.